• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Dexcom shares drop in response to ‘headwinds’ comment

September 9, 2019 By Nancy Crotti

Dexcom updated logoShares in Dexcom (NSDQ:DXCM) dropped nearly 6.8% this morning following comments by a company executive that the company is facing “headwinds” that could hamper third-quarter results, according to a report by SeekingAlpha.

EVP and CFO Quentin Blakford told attendees at Morgan Stanley’s Healthcare Conference in New York that comparisons to Q3 2018 results could be difficult, and that growth will continue to be “depressed,” the SeekingAlpha report said.

Dexcom posted second-quarter results in July that beat the consensus forecast on Wall Street, and raised its outlook for the rest of the year.

The San Diego–based continuous glucose monitoring (CGM) technology company reported a loss of $10.5 million, or -$0.12 per share, on sales of $336.4 million for the three months ended June 30. Sales were up 39% compared with Q2 2018, which saw profits of $30.2 million, or $0.34 per share.

Adjusted to exclude one-time items, earnings per share were $0.08, 8¢ ahead of The Street, where analysts were looking for sales of $304.4 million.

CNBC reported in June that Dexcom was launching upgrades for its G6 diabetes system and had plans to launch its direct-to-Apple Watch version over the next year. The Apple and Dexcom collaboration would allow diabetes patients to track glucose through the Apple Watch, a consumer wearable, the network reported.

Dexcom had said in its Q2 earnings report that it expects to log a non-GAAP operating margin of roughly 7% this year, versus previous expectations of 6%, and upped its top-line outlook to $1.325 billion to $1.375 billion, compared with $1.25 billion to $1.30 billion previously.

DXCM shares were trading at $150.29 today during late-morning trading.

Filed Under: Business/Financial News, Diabetes, Featured, Uncategorized, Wall Street Beat Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS